MedTrace Logo

Rivastigmine as a Treatment for Methamphetamine Dependence

NCT01073319 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2012-07-27

No results posted yet for this study

Summary

To study the effects of treatment with rivastigmine on craving produced by experimental administration of methamphetamine.

Conditions

Interventions

OTHER

Placebo

Administration of placebo pill

DRUG

Rivastigmine

Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.

DRUG

Rivastigmine

Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Baylor College of Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01073319 on ClinicalTrials.gov